GP5

Across TCGA pan-cancer cohorts, GP5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GP5 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher GP5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GP5 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUSC, COAD, and PRAD are the cancer types where GP5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.124	0.709	<.001	18	view →
COAD	OS	Median	III,IV	0.140	0.792	<.001	9	view →
PRAD	DFS	Median	All	0.617	0.886	.041	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.545	.026	4	view →
BLCA	OS	Median	III,IV	0.195	0.684	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GP5–LUSC (DFS)

Open the LUSC breakdown →